◀ Back to RAC1
RAC1 — SMN1
Text-mined interactions from Literome
Mondin et al., Biochem Pharmacol 2007
:
Pharmacological inhibition of RhoA activity reduced expression of both SMA and calponin, whereas overexpression of a dominant negative form of
Rac1 increased
SMA expression ... Conversely, overexpression of constitutively active
Rac1 resulted in
SMA and b-calp down-regulation, and fully prevented their stimulation by MPA, indicating that Rac inactivation is responsible for MPA effects on mesangial cytoskeletal expression
Sebe et al., FEBS Lett 2008
:
Dominant negative ( DN )
Rac , DN-PAK, DN-p38, or the p38 inhibitor SB203580
suppressed the LCM induced nuclear accumulation of MRTF and the activation of the
SMA promoter
Fintha et al., Am J Pathol 2013
(Diabetic Nephropathies...) :
When co-expressed, it inhibited the stimulatory
effects of MRTF-A, MRTF-B or the constitutive active forms of RhoA,
Rac1 , or Cdc42 on the
SMA promoter